Investors should not be able to justify seeing Kaleido (KLDO) with an enterprise value of $462 million. There are two reasons. Firstly, peers with more advanced stage of development and more product candidates are trading with an enterprise value of $77-$245 million. In addition, the market opportunity for the company’s leading candidate is not that large. Potential worldwide market opportunity for product candidates targeting hyperammonemia with urea cycle defects is approximately $300 to $500 million.
Source: Prospectus
Source: Prospectus
The company may reach large capitalizations when the new data is released in 2020. With that,